General
Preferred name
givinostat
Synonyms
ITF2357 hydrochloride ()
ITF2357 HCl ()
ITF-2357 HCl ()
Givinostat HCl ()
ITF 2357 HCl ()
Gavinostat hydrochloride monohydrate ()
ITF-2357 hydrochloride monohydrate ()
Givinostat hydrochloride ()
ITF 2357 ()
ITF2357 (Givinostat) ()
ITF2357 ()
Givinostat (hydrochloride) ()
Givinostat (hydrochloride monohydrate) ()
ITF-2357 ()
ITF-2357 hydrochloride ()
Givinostat (ITF2357) ()
Givinostat hydrochloride monohydrate ()
ITF2357 hydrochloride monohydrate ()
ITF2357 HYDROCHLORIDE ()
Duvyzat ()
P&D ID
PD046520
CAS
732302-99-7
199657-29-9
497833-27-9
Tags
available
drug
nuisance
obsolete probe
Drug indication
Myelofibrosis
Duchenne dystrophy
Essential thrombocythemia
Chronic lymphocytic leukemia
Polycythemia vera
Drug Status
approved
investigational
Max Phase
4.0
First approval
2024
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.
PRICE 73
DESCRIPTION Givinostat is a pan-histone deacetylase (HDAC) inhibitor . The clinically used formulation contains the hydrochloride (PubChem CID 52914048). (GtoPdb)
DESCRIPTION Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat can be used for Duchenne muscular dystrophy (DMD) research[1].
DESCRIPTION Givinostat (ITF-2357) hydrochloride is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively[1][2][3].
PRICE 119
DESCRIPTION Givinostat hydrochloride monohydrate (ITF2357) is an HDAC inhibitor. (TargetMol Bioactive Compound Library)
DESCRIPTION Givinostat (INN) or gavinostat, aslo known as ITF2357, is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas), and has been granted orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis and polycythaemia vera. ITF2357 was discovered at Italfarmaco of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005. (BOC Sciences Bioactive Compounds)
DESCRIPTION High affinity JNK inhibitor; also inhibits HCMV replication (Tocris Bioactive Compound Library)
DESCRIPTION Givinostat is an inhibitor of histone deacetylase. Givinostat has been used in trials studying the treatment of Polycythemia Vera, Juvenile Idiopathic Arthritis, Duchenne Muscular Dystrophy, Chronic Myeloproliferative Neoplasms, and Polyarticular Course Juvenile Idiopathic Arthritis. (Enamine Bioactive Compounds)
DESCRIPTION Givinostat hydrochloride (ITF2357 hydrochloride) is an inhibitor of HDAC with IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat hydrochloride exhibits anti-inflammatory, anti-angiogenic, and antineoplastic activities. (TargetMol Bioactive Compound Library)
Cell lines
2
Organisms
1
Compound Sets
21
AdooQ Bioactive Compound Library
A10488
BOC Sciences Bioactive Compounds
givinostat-cas-497833-27-9-item-84-93097
Cayman Chemical Bioactives
11045
ChEMBL Approved Drugs
CHEMBL6068400
CHEMBL1213492
ChEMBL Drugs
CHEMBL6068400
CHEMBL1213492
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB12645
DrugBank Approved Drugs
DB12645
DrugMAP
DMFZBNE
Enamine Bioactive Compounds
EBC-251046
Enamine BioReference Compounds
Guide to Pharmacology
7490
MedChem Express Bioactive Compound Library
HY-14842B
HY-14842
HY-14842A
Nuisance compounds in cellular assays
Obsolete Compounds
givinostat
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
Selleckchem Bioactive Compound Library
ITF2357(Givinostat)
TargetMol Bioactive Compound Library
T6279
T6279L
Tocris Bioactive Compound Library
6249
External IDs
54
Properties
(calculated by RDKit )
Molecular Weight
421.2
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
4.55
TPSA
90.9
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
6.0
QED
0.37
Structural alerts
2
historic compounds (Chemical Probes.org)
Obsolete
Nonspecific HDAC inhibition
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
HD1-A
HD1-B
HD2
HDAC1
HDAC2
HDAC3
HDAC4
HDAC5
HDAC6
HDAC7
HDAC8
HDAC9
HDAC10
HDAC11
HDAC
HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Primary Target
Non-selective HDACs
MOA
Inhibitor
HDAC inhibitor
Pathway
Chromatin/Epigenetic
DNA Damage/DNA Repair
Cell Cycle/DNA Damage
Epigenetics
Source data